所有多发性硬化患者都能从系列随访MR增强扫描中获益吗?一项回顾性分析
回顾性分析138例多发性硬化患者的脑MR图像,用计算机图像比较软件在非增强FLAIR序列上评估白质病灶稳定性,并与同次扫描增强T1序列的强化病灶对照。33次扫描显示白质病灶负荷增加,其中14次同时有新强化病灶;所有强化病灶均伴非增强图像上的进展。作者认为在复发缓解型多发性硬化中,可考虑仅对非增强MR显示进展的患者使用对比剂。
要点
- 所有出现强化病灶的患者在非增强图像上均有病灶进展证据。
- 138例患者中仅24%的扫描显示病灶进展,进展者中14次伴新强化病灶。
- 作者认为复发缓解型多发性硬化可考虑仅对非增强MR显示进展者使用对比剂。
核心结论
- 所有强化病灶均伴非增强图像上的新发病灶,且仅24%的患者显示进展,作者认为在复发缓解型多发性硬化中可考虑仅对非增强MR显示进展的患者保留对比剂使用。
研究设计与样本
- 回顾性图像分析研究,纳入138例患者的脑MRI,使用既往描述的计算机图像比较软件在非增强FLAIR序列上评估多发性硬化白质病灶的稳定或进展,并与同次扫描增强T1序列上的强化病灶进行相关性分析。
关键影像表现/征象
- 33次扫描显示白质病灶负荷增加,其中14次检查同时显示新的强化病灶。
- 发现1例原有白质病灶在大小上看似不变但出现强化,但同次检查显示整体病灶负荷增加并伴其他新病灶强化。
- 所有伴有强化病灶的患者在非增强影像上均有进展证据。
临床应用与阅片要点
- 在复发缓解型多发性硬化随访中,作者认为可考虑仅对非增强MR图像显示进展的患者使用对比剂。
- 阅片时需结合非增强FLAIR序列评估白质病灶负荷变化,强化病灶均伴随非增强图像上的新发病灶。
局限性
- 本文为回顾性图像分析研究。
- 作者在结论中提出需进一步研究以验证该策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Patients with multiple sclerosis routinely have MR imaging with contrast every 6-12 months to assess response to medication. Multiple recent studies provide evidence of tissue deposition of MR imaging contrast agents, questioning the long-term safety of these agents. The goal of this retrospective image-analysis study was to determine whether contrast could be reserved for only those patients who show new MS lesions on follow-up examinations.
MATERIALS AND METHODS: We retrospectively reviewed brain MRIs of 138 patients. To increase our sensitivity, we used a previously described computerized image-comparison software to evaluate the stability or progression of multiple sclerosis white matter lesions in noncontrast FLAIR sequences. We correlated these findings with evidence of contrast-enhancing lesions on the enhanced T1 sequence from the same scan.
RESULTS: Thirty-three scans showed an increase in white matter lesion burden. Among those 33 patients, 14 examinations also demonstrated enhancing new lesions. While we found a single example of enhancement of a pre-existing white matter lesion that appeared unchanged in size, that same examination showed an overall increase in lesion burden with enhancement of other, new lesions. Thus, we found that all patients with enhancing lesions had evidence of progression on their noncontrast imaging.
CONCLUSIONS: Because all enhancing lesions were associated with new lesions on unenhanced imaging and progression was only evident in 24% of patients, in patients with relapsing-remitting MS, it is reasonable to consider reserving contrast for only those patients with evidence of progression on noncontrast MR images.
引用
- Mattay RR, Davtyan K, Bilello M, et al. Do All Patients with Multiple Sclerosis Benefit from the Use of Contrast on Serial Follow-Up MR Imaging? A Retrospective Analysis. AJNR Am J Neuroradiol. 2018. PMID: 30287455. doi:10.3174/ajnr.A5828
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。